FoCUS Project shares research, strategies to financially sustain new curative cell and gene therapies

Paying for Cures Event in DC to highlight proposed financing solutions
Friday, November 2, 2018

The FoCUS Project (Financing and reimbursement of Cures in the US) consortium, part of the NEWDIGS initiative at MIT (, collaboratively addresses the need for new, innovative financing and reimbursement models for durable/potentially curative therapies in the US, that ensure patient access and sustainability for all stakeholders.  

This year, the consortium has begun to build on its research and analysis by proposing groundbreaking solutions in a series of research briefs and whitepapers. It will make a major presentation of its Precision Financing tools and strategies at a February 12, 2019 in Washington, DC. 

At the public event, entitled Paying for Cures: Ensuring Patient Access and System Sustainability, the FoCUS consortium will share its research findings and proposed solutions, and engage policymakers and other healthcare system stakeholders to identify and overcome barriers to implementation.  

During the consortium’s recent Design Lab, its invitation-only biannual working meeting at MIT, major progress included: 

  • Refining durable therapy launch predictions from modeling the product development pipeline
  • Commissioning payer and patient perspectives research to elucidate these stakeholders concerns and barriers.
  • Preparing two pilot projects for 2019 to practice Precision Financing in the real world

“After two years of careful, candid collaboration to survey the challenges and plot a course through them, we feel confident we have designed financial engineering solutions ready to pilot with the healthcare community,” said Mark Trusheim, NEWDIGS Strategic Advisor and longtime FoCUS project leader. “We look forward to engaging policymakers and all other system stakeholders to appropriately advance these transformative therapies to patients.”